Fox Chase Cancer Center News

Beatrice Mintz, PhD
March 27, 2012

Beatrice Mintz, PhD, Receives Ninth Annual AACR Award for Lifetime Achievement in Cancer Research

CHICAGO (March 27, 2012) – Beatrice Mintz, PhD, professor and Jack Schultz chair in basic science at Fox Chase Cancer Center in Philadelphia, will receive the Ninth Annual AACR Award for Lifetime Achievement in Cancer Research during the opening ceremony of the AACR Annual Meeting 2012.
Crystal S. Denlinger, MD
March 18, 2012

Fox Chase Cancer Center Leads Efforts to Establish National Standards for Survivorship Care

​HOLLYWOOD, Fla. (March 18, 2012) — People are living longer with and after a cancer diagnosis, making survivorship clinics and programs—as well as official guidelines and practices governing the care of survivors—an important emerging component of modern cancer care. Many institutions are looking to gather these resources into an easily understandable plan for their survivors. Crystal S. Denlinger, MD, Assistant Professor, Gastrointestinal Oncology, a medical oncologist at Fox Chase Cancer Center who will present on best practices in cancer survivorship at the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ on March 18, 2012.

March 7, 2012

Fox Chase Selected as Candidate for Two LIVESTRONG® Community Impact Projects

PHILADELPHIA (March 7, 2012) – Fox Chase Cancer Center has been selected as a candidate for two LIVESTRONG Community Impact Projects—a program created to bring proven cancer support projects to communities across the United States.  Hundreds of qualified hospitals, cancer centers, universities, and non-profits from across the United States applied to be part of four different projects—  Creative Center: Hospital Artist in Residence, LIVESTRONG at the YMCA, Advancing Joint Commission Palliative Care Certification in Cancer Centers, and Pillars4Life.  Applicants with the top votes per region

February 15, 2012

3rd Annual GIST Benefit Ball to Benefit Fox Chase Cancer Center

PHILADELPHIA (January 15, 2012) – Beat the winter blues by attending the 3rd Annual GIST Benefit Ball––an old Hollywood themed casino night that will help raise funds for cancer research at Fox Chase Cancer Center.  The event will take place on Saturday, February 18, from 7-10 p.m. at the Rittenhouse Hotel in Philadelphia (210 West Rittenhouse Square).  Guests attending the ball will enjoy passed hors d'oeuvres and stations, dancing, silent auctions, raffles, music, and of course casino games. 

January 30, 2012

The City of Philadelphia Mural Arts Program Unveils New Mural at Fox Chase Cancer Center

PHILADELPHIA (January 30, 2012) – Fox Chase Cancer Center and the City of Philadelphia Mural Arts Program have teamed up to design and produce a new mural, entitled Pathways, that portrays Fox Chase’s three main areas of focus—bold science, breakthrough medicine, and personal touch.

January 9, 2012

Most Parents Who Get Tested for Breast Cancer Genes Share Results with their Children

PHILADELPHIA (January 9, 2012) – A new study has found that when parents get tested for breast cancer genes many of them share their results with their children—even with those who are very young. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that most parents think that their children are not distressed when they learn about the test results.  

January 3, 2012

Running to a Cure: Temple's Bone Marrow Transplant Program Celebrates 25 Years

PHILADELPHIA (January 3, 2012) - A quarter-century of life-saving patient care and advanced blood cancer research is the legacy of Temple Bone Marrow Transplant (BMT) as the program celebrates the 25th anniversary of its founding this year.

December 28, 2011

Targeted Therapy Extends Progression-Free Survival of Patients with Advanced Ovarian Cancer

PHILADELPHIA (December 28, 2011) – Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment.


Connect with Fox Chase